Literature DB >> 30635936

Brain and cord imaging features in neuromyelitis optica spectrum disorders.

Laura Cacciaguerra1,2, Alessandro Meani1, Sarlota Mesaros3, Marta Radaelli2, Jacqueline Palace4, Irena Dujmovic-Basuroski3, Elisabetta Pagani1, Vittorio Martinelli2, Lucy Matthews4, Jelena Drulovic3, Maria Isabel Leite4, Giancarlo Comi2, Massimo Filippi1,2, Maria A Rocca1,2.   

Abstract

OBJECTIVES: To validate imaging features able to discriminate neuromyelitis optica spectrum disorders from multiple sclerosis with conventional magnetic resonance imaging (MRI).
METHODS: In this cross-sectional study, brain and spinal cord scans were evaluated from 116 neuromyelitis optica spectrum disorder patients (98 seropositive and 18 seronegative) in chronic disease phase and 65 age-, sex-, and disease duration-matched multiple sclerosis patients. To identify independent predictors of neuromyelitis optica diagnosis, after assessing the prevalence of typical/atypical findings, the original cohort was 2:1 randomized in a training sample (where a multivariate logistic regression analysis was run) and a validation sample (where the performance of the selected variables was tested and validated).
RESULTS: Typical brain lesions occurred in 50.9% of neuromyelitis optica patients (18.1% brainstem periventricular/periaqueductal, 32.7% periependymal along lateral ventricles, 3.4% large hemispheric, 6.0% diencephalic, 4.3% corticospinal tract), 72.2% had spinal cord lesions (46.3% long transverse myelitis, 36.1% short transverse myelitis), 37.1% satisfied 2010 McDonald criteria, and none had cortical lesions. Fulfillment of at least 2 of 5 of absence of juxtacortical/cortical lesions, absence of periventricular lesions, absence of Dawson fingers, presence of long transverse myelitis, and presence of periependymal lesions along lateral ventricles discriminated neuromyelitis optica patients in both training (sensitivity = 0.92, 95% confidence interval [CI] = 0.84-0.97; specificity = 0.91, 95% CI = 0.78-0.97) and validation samples (sensitivity = 0.82, 95% CI = 0.66-0.92; specificity = 0.91, 95% CI = 0.71-0.99). MRI findings and criteria performance were similar irrespective of serostatus.
INTERPRETATION: Although up to 50% of neuromyelitis optica patients have no typical lesions and a relatively high percentage of them satisfy multiple sclerosis criteria, several easily applicable imaging features can help to distinguish neuromyelitis optica from multiple sclerosis. ANN NEUROL 2019;85:371-384.
© 2019 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30635936     DOI: 10.1002/ana.25411

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  10 in total

1.  A Rare Case of Neuromyelitis Optica Spectrum Disorders With Unknown Fever and Subacute Cognitive Decline With Normal Images.

Authors:  Kento Furuya; Naoya Itoh
Journal:  Cureus       Date:  2022-05-12

Review 2.  Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management.

Authors:  Elia Sechi; Laura Cacciaguerra; John J Chen; Sara Mariotto; Giulia Fadda; Alessandro Dinoto; A Sebastian Lopez-Chiriboga; Sean J Pittock; Eoin P Flanagan
Journal:  Front Neurol       Date:  2022-06-17       Impact factor: 4.086

3.  Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.

Authors:  Haojie Xie; Yingzhe Shao; Juan Du; Yajun Song; Yanfei Li; Ranran Duan; Yaobing Yao; Zhe Gong; Junfang Teng; Yanjie Jia
Journal:  J Neurol       Date:  2021-08-12       Impact factor: 4.849

Review 4.  A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course.

Authors:  Jacqueline M Solomon; Friedemann Paul; Claudia Chien; Jiwon Oh; Dalia L Rotstein
Journal:  Ther Adv Neurol Disord       Date:  2021-05-09       Impact factor: 6.570

5.  Mirror-Image Lesions in Sequential Relapses of AQP4-Positive Neuromyelitis Optica Spectrum Disorder.

Authors:  Ryan T Muir; Aditya Bharatha; Dalia Rotstein
Journal:  Front Neurol       Date:  2020-05-12       Impact factor: 4.003

Review 6.  Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.

Authors:  Massimo Filippi; Paolo Preziosa; Brenda L Banwell; Frederik Barkhof; Olga Ciccarelli; Nicola De Stefano; Jeroen J G Geurts; Friedemann Paul; Daniel S Reich; Ahmed T Toosy; Anthony Traboulsee; Mike P Wattjes; Tarek A Yousry; Achim Gass; Catherine Lubetzki; Brian G Weinshenker; Maria A Rocca
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

Review 7.  Epidemiology of neuromyelitis optica spectrum disorder in Denmark (1998-2008, 2007-2014).

Authors:  Nasrin Asgari; Soeren T Lillevang; Hanne P B Skejoe; Kirsten O Kyvik
Journal:  Brain Behav       Date:  2019-06-11       Impact factor: 2.708

8.  3D Compressed Convolutional Neural Network Differentiates Neuromyelitis Optical Spectrum Disorders From Multiple Sclerosis Using Automated White Matter Hyperintensities Segmentations.

Authors:  Zhuo Wang; Zhezhou Yu; Yao Wang; Huimao Zhang; Yishan Luo; Lin Shi; Yan Wang; Chunjie Guo
Journal:  Front Physiol       Date:  2020-12-23       Impact factor: 4.566

Review 9.  Update on neuromyelitis optica spectrum disorder.

Authors:  Kathryn B Holroyd; Giovanna S Manzano; Michael Levy
Journal:  Curr Opin Ophthalmol       Date:  2020-11       Impact factor: 4.299

10.  Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.

Authors:  Maciej Juryńczyk; Elżbieta Klimiec-Moskal; Yazhuo Kong; Samuel Hurley; Silvia Messina; Tianrong Yeo; Mark Jenkinson; Maria Isabel Leite; Jacqueline Palace
Journal:  J Neurol       Date:  2021-05-27       Impact factor: 4.849

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.